

MARK S DACEY, M.D.

CURRENT POSITIONS

Director of Uveitis Service, Colorado Retina Associates, Denver, CO
Assistant Clinical Professor of Ophthalmology, University of Colorado, Aurora, CO

EDUCATION

1996-2000 *B.S.*, Biology and Political Science, Duke University, Durham, NC
2001-2005 *M.D.*, University of Michigan Medical School, Ann Arbor, MI
2005-2006 *Internship*, Department of Internal Medicine, Presbyterian Hospital of Dallas, Dallas, TX
2006-2009 *Residency*, Department of Ophthalmology, The University of Texas Southwestern Medical School and Parkland Memorial Hospital, Dallas, TX
2009-2010 *Fellowship*, Ocular Immunology and Uveitis, Harvard University, Massachusetts Eye Research and Surgery Institution, Cambridge, MA.
Mentor: C. Stephen Foster, M.D.

BOARD CERTIFICATION

2011-2021 Diplomate, American Board of Ophthalmology

AWARDS

2005 Dean's Scholarship in Ophthalmology, University of Michigan Medical School
2009-2010 Chief Fellow, Massachusetts Eye Research and Surgery Institution

PROFESSIONAL ORGANIZATIONS AND SOCIETIES

2006-present American Academy of Ophthalmology
2006-present American Society Cataract and Refractive Surgery
2015-present International Ocular Inflammation Society
2017-present American Uveitis Society

RESEARCH INTERESTS and ACTIVITIES

1. Chemotherapeutic agents in the treatment of uveitis and ocular inflammation
2. Hereditary ophthalmologic diseases
3. Ocular oncology

PUBLICATIONS/PRESENTATIONS/TEXTBOOKS

1. Oliver GP et al. **Dacey M** as member of International Ocular Syphilis Study Group. “Current Ophthalmology Practice Patterns for Syphilitic Uveitis”. *Br J Ophthalmol* 15 Jan 2019.
2. Sepah YJ, Sadiq MA, Chu DS, **Dacey M**, Gallemore R, Dayani P, Hanout M, Hassan M, Afridi R, Agarwal A, Halim MS, Do DV, Nguyen QD. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients With Noninfectious Uveitis. *Am J Ophthalmol* 2017 Nov;183:71-80
3. Larochelle MB, Smith J, **Dacey MS**. Dexamethasone Intravitreal Implant in the Treatment of Uveitic Macular Edema in the Perioperative Cataract Setting: A Case Series. *Am J Ophthalmol* 2016 Jun;166 149-153.
4. Uveitis. Papaliodis GN et al, textbook chapter (**Dacey M**) “Ankylosing Spondylitis”, Springer Publishing 2016.
5. Cao J, Mulvahill M, Zhang L, Joondeph B, **Dacey M**. Dexamethasone intravitreal implant in the treatment of recalcitrant uveitic macular edema in the absence of active inflammation. *Ophthalmology* 2014 Jun 3.
6. Bhandari R, **Dacey M**, Schwartz S, Olson J, Quiroz-Mercado H, Mandava N, Oliver S. Vogt–Koyanagi–Harada disease masquerading as a lymphoproliferative process of the uvea *Br J Ophthalmol* 2 August 2013
7. Shaikh M, Siddique S, **Dacey M**, Foster CS. Cytosine Arabinoside for the treatment of ocular inflammatory disorders: a pilot study. *Invest Ophthalmol Vis Sci* 2013; 54.
8. Foster CS, **Dacey M**, Tehrani N, Ainsworth J, Braverman RS. The new age of medical management of pediatric non-infectious uveitis. American Association of Pediatric Ophthalmology and Strabismus Annual Meeting, Boston, MA, April 5, 2013.

-
9. Curbside Consultation in Uveitis: 49 Clinical Questions, Foster CS. Chapter (**Dacey M**): What Are Some Important Associations Between Human Leukocyte Antigen Phenotypes and Specific Uveitis Syndromes? Slack Incorporated; February 15, 2012.
 10. Hinkle DM, **Dacey M**, Mandelcorn E, Kalyani P, Mauro J, Bates JH, Soukasian SH, Holland GN, Foster CS, Fraunfelder FT, Davis JL, Fraunfelder FW. Bilateral uveitis associated with fluoroquinolone therapy. *Cutan Ocul Toxicol*, 2011 Oct 8.
 11. **Dacey M**. Steroid-sparing immunomodulatory therapy for orbital and ocular adnexal disease. Platform presentation at ASOPRS meeting, May 2011.
 12. Sheikh M, **Dacey M**, Siddique S, Diaz M, Amorese L, Foster CS. Infliximab therapy for ocular inflammatory disease. Poster presentation at ARVO, May 2011.
 13. Mehta M, **Dacey M**, Foster CS. Recurrent conjunctivitis and scleritis secondary to coexistent conjunctival pemphigus vulgaris and cryptic herpes simplex infection. A case report. *Ocular Immunology and Inflammation*. 2010: 0927-3948 print/ 1744-5078 online.
 14. Amorese L, **Dacey M**, Rosenbaum R, Foster CS. *Birdshot Retinochoroidopathy*. Lulu Publishing: 2010.
 15. Amorese L, **Dacey M**, Jancevski M, Foster CS. Atypical Presentation of Von HippelLindau Disease Masquerading as Recalcitrant Posterior Scleritis: a case report. Poster presentation at ARVO, May 2010.
 16. **Dacey M**, Callanan D. Anecortave Acetate for Intraocular Pressure Control in Patients with a Retisert Implant. Paper presented at Annual UT Southwestern Ophthalmology Alumni Day, June 2009.
 17. **Dacey M**, Wang R. Visual Outcomes of Pars Plana Vitrectomy as Initial Treatment for Patients with Acute Retinal Necrosis. Paper presented at Annual UT Southwestern Ophthalmology Alumni Day, June 2008.
 18. Chang B, **Dacey M**, Hawes N, Hitchcock P, Milam A, Atmaca-Sonmez P, Nusinowitz S, Heckenlively J. Photoreceptor Function Loss-3, a Novel Mouse Model of Achromatopsia Due to a Mutation in Gnat2. *Investigative Ophthalmology and Visual Science*. 2006;47: 5017-5021
 19. Jackson A, Palmer S, Davis RD, Pappendick A, Pearson E, Savik K, Ormaza S, Hertz M, **Dacey M**, Miller L, Reinsmoen NL. Cytokine genotypes in kidney, heart, and lung recipients: consequences for acute and chronic rejection. *Transplant Proc*. 2001 Feb-Mar; 33 (1-2): 489-0.

CLINICAL RESEARCH EXPERIENCE

Primary Investigator: STOP-Uveitis, Novartis AIN457, XOMA 130/131/132, EyeGate iontophoresis, Alcon Difluprednate for anterior uveitis, Novartis CLFG316A2204, ACTHar gel for uveitis and scleritis, Filgotinib (Gilead), Clearside Peachtree clinical research trials.

INTERESTS

Hobbies include running, skiing, travel, photography, and scuba diving.